Articles

Fibrinogen interaction with complement C3: a potential therapeutic target to reduce thrombosis risk

Leeds Institute for Cardiovascular and Metabolic Medicine, Leeds, UK;
Department of Internal Medicine I, University Hospital RWTH Aachen, Germany;
Bioscreening Technology Group,School of Molecular and Cellular Biology, University of Leeds, UK;
Institute for Molecular and Cardiovascular Research, Aachen University, Germany;
Leeds Institute for Cardiovascular and Metabolic Medicine, Leeds, UK;
Leeds Institute for Cardiovascular and Metabolic Medicine, Leeds, UK;
School of Chemistry, University of Leeds, Leeds, UK;
School of Molecular and Cellular Biology, University of Leeds, Leeds, UK;
School of Medicine, University of Sheffield, Sheffield, UK;
School of Chemistry, University of Leeds, Leeds, UK;
Bioscreening Technology Group, School of Molecular and Cellular Biology, University of Leeds, UK
Bioscreening Technology Group, School of Molecular and Cellular Biology, University of Leeds, UK
Leeds Institute for Cardiovascular and Metabolic Medicine, Leeds, UK;
Vol. 106 No. 6 (2021): June, 2021 https://doi.org/10.3324/haematol.2019.239558